Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 14.17M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Less: Net income attributable to noncontrolling interests: 14.17M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox upgraded to overweight as Roku deal, ad strength lift outlook
- Nkarta Inc. (NKTX) PT Lowered to $10 at Stifel as Ntrust-1/2 Trial Enrollment Progresses
- Star Equity to acquire Harte Hanks for $5.00 per share
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
